Jing

Press ReleaseChengdu, China, May 18, 2022Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Chengdu, China, May 18, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, based in China, and DelSiTech Ltd, the leading silica drug delivery technology company, based in …

Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Read More »

Press ReleaseChengdu, China, April 19, 2022Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Chengdu, China, April 19, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that its Founder, President and CEO, Dun Yang, PhD has been named as …

Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Read More »

Press ReleaseChengdu, China, January 17, 2022Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Chengdu, China, January 17, 2022 - The Discovery Oncology (DO) group and the Natural Product Drug Discovery (NPDD) group of Anticancer Bioscience (ACB) collaboratively published another interesting study that uncovers a novel mechanism by which a natural …

Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Read More »

Press ReleaseChengdu, China, January 8, 2022Dr. Allen, VP of Anticancer Bioscience, presented his insights on personalized / precision medicine at a roundtable discussion organized by Pharma's Almanac Chengdu, China, January 8, 2022 - Dr. Thaddeus Allen, VP of Translational Biology and Business Development, was invited for a roundtable discussion by Pharma’s Almanac on January 7th, …

Dr. Allen, VP of Anticancer Bioscience, Presented His Insights on Personalized / Precision Medicine at a Roundtable Discussion Organized by Pharma’s Almanac Read More »

Press ReleaseChengdu, China, December 20, 2021Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China Chengdu, China, December 20, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that to accommodate its growth and expansion, and on the back of its recent financing, it …

Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China Read More »

PRESS RELEASEChengdu, China, September 9, 2021Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Chengdu, China, September 9, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid …

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Read More »

PRESS RELEASEChengdu, China, July 14, 2021Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Chengdu, China, July 14, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today the appointment of Dr. Hong Liu as VP of Clinical Development. A physician-scientist, he …

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Read More »